| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Nephritis | 5 | 2022 | 193 | 2.090 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 7 | 2015 | 106 | 2.080 |
Why?
|
| Glycosphingolipids | 3 | 2015 | 51 | 1.430 |
Why?
|
| Mesangial Cells | 3 | 2022 | 37 | 1.390 |
Why?
|
| Lupus Erythematosus, Systemic | 7 | 2014 | 756 | 1.280 |
Why?
|
| Promoter Regions, Genetic | 16 | 2016 | 615 | 1.250 |
Why?
|
| Neuraminidase | 3 | 2017 | 36 | 1.200 |
Why?
|
| T-Lymphocytes | 4 | 2015 | 597 | 1.050 |
Why?
|
| Gene Expression Regulation | 12 | 2016 | 1293 | 1.000 |
Why?
|
| Nuclear Proteins | 8 | 2007 | 271 | 0.820 |
Why?
|
| DNA-Binding Proteins | 11 | 2014 | 700 | 0.770 |
Why?
|
| Kidney | 4 | 2015 | 945 | 0.690 |
Why?
|
| Physicians, Women | 1 | 2018 | 23 | 0.640 |
Why?
|
| Staff Development | 1 | 2018 | 35 | 0.630 |
Why?
|
| Faculty, Medical | 1 | 2018 | 110 | 0.600 |
Why?
|
| Leadership | 1 | 2018 | 136 | 0.570 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 281 | 0.550 |
Why?
|
| Nephritis | 2 | 2015 | 37 | 0.550 |
Why?
|
| Interleukin-6 | 1 | 2017 | 330 | 0.540 |
Why?
|
| Receptors, CXCR3 | 1 | 2015 | 16 | 0.530 |
Why?
|
| Mice, Inbred MRL lpr | 5 | 2017 | 118 | 0.520 |
Why?
|
| Transcription Factors | 11 | 2007 | 753 | 0.500 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 126 | 0.500 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2014 | 9 | 0.490 |
Why?
|
| Transcription, Genetic | 8 | 2014 | 562 | 0.470 |
Why?
|
| Mice | 23 | 2016 | 8474 | 0.470 |
Why?
|
| Microsatellite Repeats | 2 | 2010 | 40 | 0.450 |
Why?
|
| Telomere | 1 | 2013 | 59 | 0.430 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2004 | 411 | 0.400 |
Why?
|
| Binding Sites | 10 | 2014 | 631 | 0.390 |
Why?
|
| Trans-Activators | 5 | 2005 | 237 | 0.390 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 3 | 2014 | 65 | 0.380 |
Why?
|
| Animals | 25 | 2017 | 20881 | 0.370 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 292 | 0.360 |
Why?
|
| Fibroblast Growth Factors | 6 | 2004 | 51 | 0.360 |
Why?
|
| Disease Models, Animal | 6 | 2017 | 2550 | 0.350 |
Why?
|
| Autoantibodies | 1 | 2011 | 434 | 0.330 |
Why?
|
| Enhancer Elements, Genetic | 4 | 2005 | 63 | 0.320 |
Why?
|
| Up-Regulation | 5 | 2017 | 682 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-ets | 3 | 2007 | 79 | 0.310 |
Why?
|
| PPAR gamma | 2 | 2005 | 95 | 0.300 |
Why?
|
| Transfection | 8 | 2014 | 782 | 0.280 |
Why?
|
| Lymphocytes | 1 | 2007 | 228 | 0.270 |
Why?
|
| Repressor Proteins | 1 | 2007 | 183 | 0.270 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 301 | 0.270 |
Why?
|
| Cell Line | 7 | 2017 | 1752 | 0.270 |
Why?
|
| Homeodomain Proteins | 2 | 2013 | 157 | 0.260 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2005 | 66 | 0.260 |
Why?
|
| Microfilament Proteins | 1 | 2005 | 102 | 0.250 |
Why?
|
| Genes, Reporter | 7 | 2005 | 191 | 0.240 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 163 | 0.240 |
Why?
|
| GATA Transcription Factors | 3 | 2009 | 7 | 0.230 |
Why?
|
| Base Sequence | 7 | 2007 | 1015 | 0.220 |
Why?
|
| Humans | 18 | 2022 | 68618 | 0.210 |
Why?
|
| Jurkat Cells | 2 | 2013 | 59 | 0.210 |
Why?
|
| Transcriptional Activation | 5 | 2014 | 226 | 0.210 |
Why?
|
| Endothelial Cells | 2 | 2016 | 384 | 0.210 |
Why?
|
| Drug Carriers | 1 | 2002 | 90 | 0.200 |
Why?
|
| Liposomes | 1 | 2002 | 107 | 0.200 |
Why?
|
| Molecular Sequence Data | 6 | 2007 | 1447 | 0.200 |
Why?
|
| Neoplastic Stem Cells | 1 | 2002 | 84 | 0.200 |
Why?
|
| Genetic Vectors | 1 | 2002 | 312 | 0.200 |
Why?
|
| DNA | 6 | 2014 | 597 | 0.190 |
Why?
|
| Antibodies, Antinuclear | 1 | 2022 | 171 | 0.190 |
Why?
|
| Protein Binding | 6 | 2016 | 1027 | 0.190 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 223 | 0.180 |
Why?
|
| Disease Progression | 2 | 2014 | 1038 | 0.180 |
Why?
|
| Fibroblast Growth Factor 4 | 7 | 2005 | 10 | 0.180 |
Why?
|
| Fibrosis | 1 | 2022 | 371 | 0.170 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2000 | 123 | 0.160 |
Why?
|
| B-Lymphocytes | 2 | 2013 | 329 | 0.160 |
Why?
|
| Career Mobility | 1 | 2018 | 34 | 0.160 |
Why?
|
| Glycoside Hydrolase Inhibitors | 1 | 2017 | 7 | 0.150 |
Why?
|
| Spinal Cord | 1 | 1999 | 244 | 0.150 |
Why?
|
| Career Choice | 1 | 2018 | 98 | 0.150 |
Why?
|
| Phosphoproteins | 1 | 1999 | 202 | 0.150 |
Why?
|
| Acetylation | 2 | 2016 | 94 | 0.150 |
Why?
|
| Program Development | 1 | 2018 | 240 | 0.140 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1999 | 328 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 3 | 2007 | 532 | 0.140 |
Why?
|
| Receptors, IgG | 1 | 2017 | 94 | 0.140 |
Why?
|
| STAT Transcription Factors | 2 | 2007 | 13 | 0.140 |
Why?
|
| Mutation | 5 | 2016 | 1213 | 0.140 |
Why?
|
| HMGB Proteins | 5 | 2004 | 6 | 0.140 |
Why?
|
| SOXB1 Transcription Factors | 5 | 2004 | 20 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2016 | 24 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2018 | 502 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2016 | 74 | 0.130 |
Why?
|
| Chemokine CXCL9 | 1 | 2015 | 8 | 0.130 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 21 | 0.130 |
Why?
|
| Lactosylceramides | 1 | 2015 | 27 | 0.130 |
Why?
|
| RNA, Messenger | 4 | 2015 | 1664 | 0.130 |
Why?
|
| Gene Expression | 2 | 2010 | 770 | 0.130 |
Why?
|
| Neutrophils | 1 | 2016 | 204 | 0.130 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 481 | 0.130 |
Why?
|
| Complement Factor B | 1 | 2015 | 19 | 0.120 |
Why?
|
| Choroid | 1 | 2015 | 22 | 0.120 |
Why?
|
| Female | 7 | 2018 | 38074 | 0.120 |
Why?
|
| Antigens, CD | 1 | 2015 | 230 | 0.120 |
Why?
|
| Urinalysis | 1 | 2014 | 27 | 0.120 |
Why?
|
| Chemokine CCL5 | 1 | 2014 | 23 | 0.120 |
Why?
|
| Choroidal Neovascularization | 1 | 2015 | 35 | 0.120 |
Why?
|
| Kidney Function Tests | 1 | 2014 | 114 | 0.120 |
Why?
|
| Complement Pathway, Alternative | 1 | 2015 | 69 | 0.120 |
Why?
|
| Immunoblotting | 1 | 2014 | 254 | 0.120 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 191 | 0.120 |
Why?
|
| Chemokine CCL2 | 1 | 2014 | 101 | 0.120 |
Why?
|
| Inflammation Mediators | 2 | 2005 | 244 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 4 | 2015 | 2791 | 0.110 |
Why?
|
| Telomere Homeostasis | 1 | 2013 | 6 | 0.110 |
Why?
|
| Interleukin-4 | 1 | 2013 | 69 | 0.110 |
Why?
|
| Cell Proliferation | 1 | 2017 | 1174 | 0.110 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 100 | 0.110 |
Why?
|
| Mice, Knockout | 2 | 2015 | 1692 | 0.110 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2004 | 56 | 0.110 |
Why?
|
| Inflammation | 2 | 2016 | 1030 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2002 | 376 | 0.110 |
Why?
|
| Cell Movement | 1 | 2015 | 630 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 135 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2014 | 1040 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1174 | 0.100 |
Why?
|
| Octamer Transcription Factor-3 | 2 | 2002 | 11 | 0.100 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 397 | 0.100 |
Why?
|
| Genotype | 2 | 2010 | 786 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1753 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2800 | 0.090 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2005 | 204 | 0.090 |
Why?
|
| Sequence Deletion | 2 | 2007 | 89 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2015 | 1033 | 0.080 |
Why?
|
| Blotting, Western | 3 | 2015 | 954 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1553 | 0.080 |
Why?
|
| Middle Aged | 3 | 2018 | 21147 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1851 | 0.080 |
Why?
|
| Biomarkers | 1 | 2014 | 1593 | 0.080 |
Why?
|
| Adult | 3 | 2018 | 21403 | 0.080 |
Why?
|
| Vitamin D | 1 | 2013 | 516 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 4 | 2002 | 852 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2017 | 2689 | 0.080 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2005 | 95 | 0.080 |
Why?
|
| Plasmids | 3 | 2005 | 258 | 0.080 |
Why?
|
| Sp1 Transcription Factor | 2 | 2014 | 21 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 3259 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2005 | 201 | 0.080 |
Why?
|
| Peroxidase | 1 | 2007 | 40 | 0.070 |
Why?
|
| Cytokines | 1 | 2011 | 866 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 786 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 159 | 0.070 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 3 | 2005 | 43 | 0.070 |
Why?
|
| Nitric Oxide | 2 | 2005 | 382 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2018 | 7277 | 0.070 |
Why?
|
| United States | 1 | 2018 | 7367 | 0.070 |
Why?
|
| High Mobility Group Proteins | 2 | 2003 | 7 | 0.070 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 2 | 2002 | 26 | 0.070 |
Why?
|
| Models, Genetic | 2 | 2005 | 161 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2007 | 447 | 0.070 |
Why?
|
| CCAAT-Binding Factor | 1 | 2005 | 2 | 0.060 |
Why?
|
| Luciferases | 1 | 2005 | 105 | 0.060 |
Why?
|
| Thiazolidinediones | 1 | 2005 | 77 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2007 | 307 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 627 | 0.060 |
Why?
|
| Male | 4 | 2017 | 37321 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2005 | 241 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 434 | 0.060 |
Why?
|
| HeLa Cells | 2 | 2003 | 237 | 0.060 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2002 | 5 | 0.050 |
Why?
|
| Physical Chromosome Mapping | 1 | 2002 | 8 | 0.050 |
Why?
|
| Embryonal Carcinoma Stem Cells | 1 | 2002 | 2 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 742 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 88 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2005 | 455 | 0.050 |
Why?
|
| Exons | 1 | 2002 | 122 | 0.050 |
Why?
|
| Chromatin | 1 | 2002 | 76 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 357 | 0.050 |
Why?
|
| Models, Biological | 2 | 2003 | 981 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2005 | 756 | 0.050 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2000 | 6 | 0.040 |
Why?
|
| Fungal Proteins | 1 | 2000 | 37 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2001 | 230 | 0.040 |
Why?
|
| DNA Footprinting | 1 | 1999 | 4 | 0.040 |
Why?
|
| Embryonic and Fetal Development | 1 | 1999 | 74 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2000 | 261 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 1999 | 201 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 3 | 2004 | 322 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2001 | 384 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2673 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 45 | 0.030 |
Why?
|
| Stem Cells | 1 | 1997 | 248 | 0.030 |
Why?
|
| Lasers | 1 | 2015 | 61 | 0.030 |
Why?
|
| Electroretinography | 1 | 2015 | 122 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2014 | 65 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 88 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 2014 | 124 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 2014 | 47 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 209 | 0.030 |
Why?
|
| Cell Differentiation | 3 | 2005 | 1034 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 507 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 266 | 0.030 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2015 | 145 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2004 | 208 | 0.030 |
Why?
|
| Carcinoma, Embryonal | 2 | 2005 | 4 | 0.030 |
Why?
|
| Random Allocation | 1 | 2007 | 442 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2005 | 100 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2005 | 52 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 132 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2004 | 57 | 0.010 |
Why?
|
| Proto-Oncogene Protein c-ets-2 | 1 | 2004 | 49 | 0.010 |
Why?
|
| Multigene Family | 1 | 2004 | 93 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2004 | 200 | 0.010 |
Why?
|
| SOXC Transcription Factors | 1 | 2003 | 4 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2004 | 305 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 189 | 0.010 |
Why?
|
| Point Mutation | 1 | 2002 | 97 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2001 | 92 | 0.010 |
Why?
|
| CHO Cells | 1 | 2001 | 161 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 262 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2007 | 2358 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 302 | 0.010 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2001 | 19 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2001 | 282 | 0.010 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2001 | 39 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2001 | 165 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 1864 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2000 | 77 | 0.010 |
Why?
|
| Chickens | 1 | 2001 | 232 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 1851 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2001 | 1200 | 0.010 |
Why?
|
| Chimera | 1 | 1997 | 33 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1997 | 58 | 0.010 |
Why?
|
| Heterozygote | 1 | 1997 | 174 | 0.010 |
Why?
|
| Tretinoin | 1 | 1997 | 92 | 0.010 |
Why?
|
| Cell Lineage | 1 | 1997 | 146 | 0.010 |
Why?
|
| Cell Survival | 1 | 1997 | 901 | 0.010 |
Why?
|
| Apoptosis | 1 | 1997 | 1641 | 0.010 |
Why?
|